Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861253 | 0.97 | OPRD1 (0.59) | OPRD1NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL30037824 | 0.85 | NTSR2 (0.73) | NTSR1NTSR2SORT1 | |
| SCHEMBL30034783 | 0.85 | NTSR2 (0.73) | NTSR1NTSR2SORT1 | |
| SCHEMBL30753221 | 0.85 | NMUR2 (0.61) | OPRD1NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL1421598 | 0.85 | NTSR1 (0.72) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL1421525 | 0.85 | NTSR1 (0.72) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL1421605 | 0.85 | NTSR1 (0.72) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL1421513 | 0.85 | NTSR1 (0.72) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL28366588 | 0.85 | NMUR2 (0.65) | NMUR2NMUR1NTSR1NTSR2 | |
| SCHEMBL29823442 | 0.84 | NMUR2 (0.62) | OPRD1NMUR2NMUR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1014 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285743-B | Anti-enzymolysis antibacterial peptide derived from pig PR-39, and preparation method and application thereof | 东北农业大学 | 2025-06-24 | — | — | CN | claimed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| CN-119285743-A | Anti-enzymolysis antibacterial peptide derived from pig PR-39, and preparation method and application thereof | 东北农业大学 | 2025-01-10 | — | — | CN | claimed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| EP-4218727-A2 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESIS | SanBio, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| CN-112402403-B | Application of deoxyshikonin in preparation of host defense peptide expression promoter | 北京市农林科学院 | 2022-06-21 | — | — | CN | claimed |
| US-20260144857-A1 | SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| CN-122094699-A | Method for coupling dialkylamines and polypeptides | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | THE CHILDRENS MEDICAL CENTER CORP (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743576-A1 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | Korro Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20220056444-A1 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | EMPIRICO INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220056455-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | disclosed |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220023405-A1 | USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES | Mendus B.V. (NL) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144857-A1 | SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF | HLA-DRB1, SPOP, STXBP1 | OPRD1 4311/4885NMUR2 3163/4885NMUR1 3513/4885 |
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | TRDMT1, METTL16, TRMT1 | OPRD1 3049/4885NMUR2 4002/4885NMUR1 3881/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | OPRD1 4554/4885NMUR2 4211/4885NMUR1 3942/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | OPRD1 1613/4885NMUR2 2244/4885NMUR1 1667/4885 |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | IGF2BP1, IGF2BP2, IGFBP1 | OPRD1 4453/4885NMUR2 3213/4885NMUR1 2728/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | OPRD1 3917/4885NMUR2 2772/4885NMUR1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.